• Profile
Close

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

The Lancet Oncology Oct 19, 2018

Velikova G, et al. - In women with intermediate-risk breast cancer, researchers evaluated the impacts of postmastectomy radiotherapy on quality of life (QOL). Up to 2 years post-randomization, more local (chest wall) symptoms were seen among patients who received postmastectomy radiotherapy vs those who did not receive radiotherapy, but the difference between groups was minor.

Methods

  • Researchers assessed 2-year QOL results (a prespecified secondary endpoint) of SUPREMO, which is an open-label, international, parallel-group, randomized, controlled trial.
  • Either chest wall radiotherapy (50 Gy in 25 fractions or a radiobiologically equivalent dose of 45 Gy in 20 fractions or 40 Gy in 15 fractions) or no radiotherapy was randomly (1:1) received by women 18 years or older with intermediate-risk breast cancer (defined as pT1–2N1; pT3N0; or pT2N0 if also grade III or with lymphovascular invasion) who had a mastectomy and, if node positive, axillary surgery.
  • Permuted blocks of varying block length were used for randomization, which was stratified by center, without masking of patients or investigators.
  • Ten-year overall survival was the primary endpoint.
  • Researchers performed this QOL substudy, which was open to all UK patients; they assessed questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23, Body Image Scale, Hospital Anxiety and Depression Scale [HADS], and EQ-5D-3L) completed before randomization, and at 1, 2, 5, and 10 years.
  • Global QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, and anxiety and depression were assessed as prespecified primary outcomes within this QOL substudy.
  • Using repeated mixed-effects methods, intention to treat data analysis was performed.

Results

  • Enrollment of 1,688 patients, internationally, as well as random assignment to chest wall radiotherapy (n=853) or no radiotherapy (n=835) was done between August 4, 2006 and April 29, 2013.
  • Consent to participate in the QOL substudy was given by 989 (79%) of 1,258 patients from 111 UK centers (487 in the radiotherapy group and 502 in the no radiotherapy group); of those, baseline questionnaires were returned by 947 and these were included in the analysis (radiotherapy, n=471; no radiotherapy, n=476).
  • The radiotherapy group vs the no radiotherapy group had worse chest wall symptoms at up to 2 years (mean score 14,1 [SD 15,8] in the radiotherapy group vs 11,6 [14,6] in the no radiotherapy group; effect estimate 2,17, 95% CI 0,40–3,94; p=0,016); however, an improvement was seen in both groups between years 1 and 2 (visit effect −1,34, 95% CI −2,36 to −0,31; p=0,010).
  • Between treatment groups, arm and shoulder symptoms, body image, fatigue, overall QOL, physical function, or anxiety or depression scores were not different.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay